Apeiron Investment Group

Enhanced Games is a modern alternative to the Olympic Games, providing a platform for athletes to compete without the restrictions of drug testing. The organization focuses on allowing the use of substances typically banned in elite sports, promoting a community where athletes can maximize their potential. By emphasizing the medical and scientific aspects of performance enhancement, Enhanced Games aims to support athletes in achieving their best while ensuring they are compensated fairly for their efforts.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

nextmarkets GmbH, founded in 2014 and headquartered in Cologne, Germany, specializes in developing a user-friendly web and mobile trading platform aimed at private investors. The platform allows users to intuitively trade a wide range of financial instruments, including equities, foreign exchange, bonds, and commodities. Recognizing the challenges faced by private investors—many of whom struggle in the stock market due to behavioral economic factors—nextmarkets provides educational resources and trading strategies to enhance users' understanding of market dynamics. By equipping investors with the necessary tools and knowledge, nextmarkets aims to promote sustainable and informed trading practices.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

Mynaric AG specializes in laser communication solutions for high data rate and long-distance wireless data transmission between moving objects. Founded in 2009 and headquartered in Gilching, Germany, the company develops a range of products including air-to-ground, air-to-air, and space terminals, as well as optical ground stations. These systems are essential for aerospace communication networks, enabling ultra-high data rates and secure connectivity for applications across terrestrial, airborne, and space environments. Mynaric operates in two primary segments: Air, which includes HAWK terminals, and Space, featuring CONDOR terminals. Its innovative technology supports a variety of applications such as satellite constellations and high-altitude networks, positioning the company at the forefront of the communication equipment sector. Additional locations in Los Angeles and Washington, D.C. expand its operational reach.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Upmin is an online platform that serves as a digital property manager, designed to streamline real estate management for owners and landlords. By automating various processes, Upmin significantly reduces the manual labor typically associated with property management, leading to time and cost savings. The platform offers a comprehensive suite of services, including accounting, utility bill management, deposit management, rent collection, tenant and property management, contract management, and maintenance. Additionally, Upmin provides an optional rental package that assists clients in tenant acquisition, encompassing advertising, marketing, property viewings, and tenant handover. This all-inclusive approach allows property owners to efficiently manage their assets with minimal stress.

Olsam Group is a technology-driven commerce company that specializes in acquiring and operating leading Amazon third-party and direct-to-consumer eCommerce brands on a global scale. The company conducts thorough due diligence on potential acquisitions, structures equitable cash deals, and transfers assets such as website domains and software tools to its ownership. Once acquired, Olsam focuses on scaling these brands through strategic capital investment and supply chain expertise. This approach allows business owners the flexibility to fully exit their operations or remain involved as desired.

Isar Aerospace is a space technology company specializing in the development of automated production methods for rockets. The company focuses on providing launch services that facilitate the deployment and resupply of satellite constellations, aimed at offering low-cost and flexible access to space for small satellites. By prioritizing affordability and sustainability, Isar Aerospace enables clients to utilize environmentally friendly solutions for launching small payloads and upper-stage vehicles.

Ksana Health is a company based in Eugene, Oregon, founded in 2019, that specializes in digital mental health solutions. The company has developed a platform aimed at collecting and transferring mental health data from users to healthcare practitioners via an app. This platform provides personalized behavioral insights and just-in-time interventions, enabling continuous remote monitoring of patients. Additionally, it offers digital therapeutics designed to enhance mental health outcomes. Through its innovative approach, Ksana Health seeks to improve the accessibility and effectiveness of mental health care.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

MagForce AG is a medical device company based in Berlin, Germany, specializing in nanotechnology-based cancer treatment. The company has developed NanoTherm therapy, which targets solid tumors by generating localized heat through the activation of superparamagnetic nanoparticles. Its product offerings include NanoTherm, a ferrofluid containing superparamagnetic iron oxide nanoparticles that respond to alternating magnetic fields, and NanoActivator, a device that applies the magnetic field for therapeutic purposes. Additionally, MagForce provides NanoPlan, a software tool that assists in treatment planning using bioheat transfer equations. Founded in 1997, MagForce focuses on innovative solutions to enhance cancer treatment efficacy.

Isar Aerospace is a space technology company specializing in the development of automated production methods for rockets. The company focuses on providing launch services that facilitate the deployment and resupply of satellite constellations, aimed at offering low-cost and flexible access to space for small satellites. By prioritizing affordability and sustainability, Isar Aerospace enables clients to utilize environmentally friendly solutions for launching small payloads and upper-stage vehicles.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Hotelbird is a developer of a mobile application aimed at digitizing the hotel experience, enhancing both operational efficiency for hotel managers and overall guest satisfaction. The application facilitates essential services such as direct booking, digital check-in and check-out, and room key access, creating a seamless journey for guests. By integrating these features, Hotelbird helps hotels streamline their processes, reduce operational costs, and ultimately increase revenue. The company's mission focuses on equipping hosts with the core technology needed to operate profitably while ensuring a high-quality experience for their guests.

Zenhomes provides a one-stop shop for private landlords and property managers. The company's digital platform simplifies property and tenant management.

Springlane GmbH is an online retailer specializing in kitchen and cooking products, established in 2012 and headquartered in Düsseldorf, Germany. Initially launched as a shopping club for cooking enthusiasts, it has evolved into a leading platform in its sector, offering over 15,000 products from 750 premium brands, including kitchen appliances, barbecues, cooking accessories, and tableware. Springlane employs advanced business intelligence technology and a content-driven e-commerce strategy to enhance customer acquisition and retention. Since 2018, the company has focused on developing integrated consumer brands and has become one of the most influential food content websites in Europe, with sales extending across Germany, Austria, the UK, France, Italy, and Spain.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Juvenescence Limited is a British Virgin Islands-based holding company focused on investing in the fields of human aging and longevity. The company aims to develop a comprehensive ecosystem of assets that target aging, age-related diseases, and regenerative medicine. By leveraging advancements in scientific and medical research, Juvenescence seeks to create therapeutics that significantly extend both healthspan and lifespan. Their approach involves forming partnerships with leading scientists and research institutions, in-licensing compounds from academia and industry, and developing novel therapies based on a deep understanding of the biological mechanisms of aging. Juvenescence's initiatives also encompass therapeutic strategies aimed at promoting healthy aging, metabolic health, and brain health, with the ultimate goal of addressing the societal implications of an aging population.

Super Copper Corp is an emerging mining exploration company focused on copper.It is developing its project in Atacama, Chile, a region with world-class infrastructure and the presence of global majors.